What we're working on

Article

The time has come to paginate our summer issue. Now that all of our editorial reviews of the summer's content and design are concluded, we're ready to determine the order of the pages. It may sound simple, but it's not. More art than science, the pagination process cannot be easily "programmed" by software developers. It's like putting together a complicated jigsaw puzzle. It requires a human touch.Because CURE is free to cancer patients, survivors and caregivers, we rely heavily on advertising revenues. Most of our advertisers are pharmaceutical companies whose ads are strictly monitored by the Food and Drug Administration. That means that any drug that is advertised must be accompanied by "patient information," usually a page or two that most readers gloss over. When we lay out our pages, we must pay attention to how those ads have been sold: some advertisers pay a premium to have their ads placed in the first third of the magazine, others prefer the inside back cover, still others may have response cards that require a certain number of pages in between, and so on. To further complicate the process, we work very hard to avoid any appearance of being influenced by an advertiser. Consequently, if we report on a particular drug – positively or negatively – we will not place that drug manufacturer's advertisement anywhere near the story. And we always try to honor an advertiser's request to avoid having an ad place next to a competitor's. Once the ads have been placed, we can begin to determine how the editorial content will be laid out. It is standard practice in the magazine industry to consistently place "front-of-book" departments first, followed by the main stories in what we call the "feature well," and then the content for the "back-of-book" departments. Several departments, categorized as "run-of-book," can be placed almost anywhere that we deem acceptable or desirable.Our "front-of-book" departments include the Table of Contents, Masthead, Editor's Page, Letters and First Line. Our "feature well" includes three main stories and four secondary stories (what we refer to as "minifeatures"). And our "back-of-book" departments include Pipeline, Voices and Speaking Out. A particular challenge in laying out our summer issue will be holding open two pages for our breaking news coverage from the American Society of Clinical Oncology (ASCO) annual meeting in June. In fact, we'll be coordinating efforts in Chicago and Dallas to complete those two pages on the very day the magazine is sent to the printer. Start the presses!

Related Videos
Jessica McDade, B.S.N., RN, OCN, in an interview with CURE
Image of Meaghan Mooney at the 2024  Extraordinary Healer Award event.
Video 4 - "Current First-Line Treatment Options in CLL"
Video 3 - "Goals of Treatment for Patients With CLL"
Image of a woman with short blonde hair wearing a white blazer.
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL